A Phase 1/2a Open-Label Study to Investigate the Safety of the Transplantation (by Injection) of Human Glial Restricted Progenitor Cells (hGRPs; Q-Cells) Into Subjects With Transverse Myelitis (TM)
Status: Not yet recruiting
Phase of Trial: Phase I/II
Latest Information Update: 13 Sep 2019
Price : $35 *
At a glance
- Drugs Glial stem cell therapy (Primary)
- Indications Transverse myelitis
- Focus Adverse reactions; First in man
- Sponsors Q Therapeutics
- 10 Sep 2019 Planned initiation date changed from 1 Jun 2019 to 20 Dec 2019.
- 20 Mar 2019 Status changed from planning to not yet recruiting.
- 27 Jul 2017 New trial record